Table 1. Baseline Demographic and clinical characteristics of study patients on isoniazid preventive therapy in Ethiopia, September 2005 to October 2013 (n = 4,484).
| Variable | Sub-category | Breakthrough TB (Row %) |
TB after IPT completion, (Row %) | Total |
|---|---|---|---|---|
| Age | <15 | 2 (0.4%) | 4 (0.8%) | 483 |
| ≥15 | 22 (0.5%) | 60 (1.5%) | 4001 | |
| Gender | Female | 13 (0.5%) | 37 (1.3%) | 2854 |
| Male | 11 (0.7%) | 27 (1.7%) | 1630 | |
| Baseline WHO Stage | I or II | 8 (0.5%) | 24 (1.4%) | 1760 |
| III or IV | 16 (0.6%) | 40 (1.5%) | 2724 | |
| Baseline CD4 Count | <100 | 5 (0.6%) | 13 (1.6%) | 801 |
| 100–349 | 13 (0.5%) | 43 (1.6%) | 2670 | |
| ≥350 | 6 (0.6%) | 8 (0.8%) | 1013 | |
| Treatment Status* | IPT only | 9 (1.0%) | 20 (2.2%) | 906 |
| ART and IPT | 15 (0.4%) | 44 (1.2%) | 3578 | |
| Grand total | 24 (0.5%) | 64 (1.4%) | 4484 |
*Chi2P value = 0.009; P value for other variables is >0.05.